A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy - Takeaways - MDSpire

A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy

  • By

  • Jan Kuska

  • Julia Kostyra

  • Lorraine Pinot

  • Evgeny Egorov

  • Nojan Jelveh

  • Lilian A. Martinez Carrera

  • Congcong Zhang

  • Svetlana Khorkova

  • Mario Assenmacher

  • Rimas Orentas

  • Sabine Mueller

  • José Villacorta Hidalgo

  • May 22, 2026

  • 0 min

Share

  • 1

    γδ T cells, particularly Vγ9Vδ2 T cells, are promising for adoptive immunotherapy due to their safety and antitumor activity.

  • 2

    An automated platform using CliniMACS Prodigy enables efficient expansion and production of CAR-γδ T cells, ensuring GMP compliance.

  • 3

    The process achieved a 374-fold increase in Vγ9Vδ2 T cells, yielding an average of 6.64 x 10^9 cells after 14 days.

  • 4

    Transduction efficiency of CAR-γδ T cells was 57.4%, with a low vector copy number indicating safety of the protocol.

  • 5

    Functional assays confirmed robust anti-tumor activity of CAR-γδ T cells, supporting their potential in clinical immunotherapy.

Original Source(s)

A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy

  • by Jan Kuska, Julia Kostyra, Lorraine Pinot, Evgeny Egorov, Nojan Jelveh, Lilian A. Martinez Carrera, Congcong Zhang, Svetlana Khorkova, Mario Assenmacher, Rimas Orentas, Sabine Mueller, José Villacorta Hidalgo

  • May 22, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

High-grade astrocytoma with piloid features: a case report of comprehensive management

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities